Electrolytes Play a Role in Detecting Cisplatin-Induced Kidney Complications and May Even Prevent Them—Retrospective Analysis

Autor: Bahauddeen M. Alrfaei, Abdulaziz O. Almutairi, Alaa A. Aljohani, Hajar Alammar, Abdulaziz Asiri, Yahya Bokhari, Feda S. Aljaser, Manal Abudawood, Majed Halwani
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Medicina, Vol 59, Iss 5, p 890 (2023)
Druh dokumentu: article
ISSN: 1648-9144
1010-660X
DOI: 10.3390/medicina59050890
Popis: Background and Objective: Cisplatin is a chemotherapy drug used to treat several types of malignancies. It is a platinum-based compound that interferes with cell division and DNA replication. Cisplatin has been associated with renal damage. This study evaluates the early detection of nephrotoxicity through routine laboratory tests. Materials and Methods: This is a retrospective chart review based on the Saudi Ministry of National Guard Hospital (MNGHA). We evaluated deferential laboratory tests for cancer patients treated with cisplatin between April 2015 and July 2019. The evaluation included age, sex, WBC, platelets, electrolytes, co-morbidities and interaction with radiology. Results: The review qualified 254 patients for evaluation. Around 29 patients (11.5%) had developed kidney function abnormality. These patients presented with abnormally low magnesium 9 (31%), potassium 6 (20.7%), sodium 19 (65.5%) and calcium 20 (69%). Interestingly, the whole sample size had abnormal electrolytes presenting magnesium 78 (30.8%), potassium 30 (11.9%), sodium 147 (58.1%) and calcium 106 (41.9%). Some pathological features were detected, such as hypomagnesemia, hypocalcemia and hypokalemia. In addition, infections that needed antibiotics were dominant in patients treated with cisplatin alone, representing 50% of this group. Conclusions: We report that an average of 15% of patients with electrolyte abnormalities develop renal toxicity and reduced function. Moreover, electrolytes may serve as an early indicator for renal damage as part of chemotherapy complication. This indication represents 15% of renal toxicity cases. Changes in electrolyte levels have been reported with cisplatin. Specifically, it has been linked to hypomagnesemia, hypocalcemia and hypokalemia. This study will help reduce the risk of dialysis or the need for kidney transplant. It is also important to manage any underlying conditions and control patients’ intake of electrolytes.
Databáze: Directory of Open Access Journals
Externí odkaz: